RETROSPECTIVE STUDY OF ERLOTINIB IN PREVIOUSLY TREATED NSCLC PATIENTS WITH WILD-TYPE EGFR

被引：0
|
作者：
Nakahara, Yoshiro [1 ]
Hosomi, Yukio [1 ]
Yomota, Makiko [1 ]
Okuma, Yusuke [1 ]
Takagi, Yusuke [1 ]
Iguchi, Mari [1 ]
Okamura, Tatsuru [1 ]
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期
关键词：
wild-type EGFR; Erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-034
引用
下载
收藏
页码：S490 / S490
页数：1
相关论文
共 50 条
  • [31] High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
    Perng, Reury-Perng
    Yang, Chih-Hsin
    Chen, Yuh-Min
    Chang, Gee-Chen
    Lin, Meng-Chih
    Hsieh, Ruey-Kuen
    Chu, Nei-Min
    Lai, Ruay-Sheng
    Su, Wu-Chou
    Tsao, Chao-Jung
    Hsia, Te-Chun
    Chen, Hao-Cheng
    Chen, Chih-Hung
    Huang, Ming-Shyan
    Wang, Jui-Long
    Ho, Ming-Lin
    Chung, Chih-Yuan
    Yu, Chong-Jen
    Chang, Wen-Cheng
    Kuo, Han-Pin
    Yu, Chih-Teng
    Lin, Zhong-Zhe
    Kao, Woei-Yau
    LUNG CANCER, 2008, 62 (01) : 78 - 84
  • [32] Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene
    Fiala, Ondrej
    Pesek, Milos
    Finek, Jindrich
    Svaton, Martin
    Minarik, Marek
    Benesova, Lucie
    Bortlicek, Zbynek
    Kucera, Radek
    Topolcan, Ondrej
    ANTICANCER RESEARCH, 2016, 36 (01) : 447 - 453
  • [33] Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients
    Winther-Larsen, Anne
    Fledelius, Joan
    Demuth, Christina
    Bylov, Catharina M.
    Meldgaard, Peter
    Sorensen, Boe S.
    TRANSLATIONAL ONCOLOGY, 2016, 9 (06): : 505 - 511
  • [34] Outcomes in Latin American NSCLC patients harboring wild-type or activating mutations of EGFR (CLICaP Registry).
    Cardona Zorrilla, Andres Felipe
    Arrieta, Oscar
    Federico Bramuglia, Guillermo
    Delia Campos-Parra, Alma
    Becerra Ramirez, Henry Alberto
    MARCELO Claudio, Martin
    Richardet, Eduardo
    Serrano, Silvia J.
    Archila, Pilar
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Patritumab plus Erlotinib in EGFR Wild-Type Advanced Non Small Cell Lung Cancer (NSCLC): Part a Results of HER3-Lung Study
    Paz-Arez, Luis
    Serwatowski, Piotr
    Szczesna, Aleksandra
    Von Pawel, Joachim
    Toschi, Luca
    Tibor, Csoszi
    Morabito, Alessandro
    Zhang, Ling
    Shuster, Dale
    Chen, Shuquan
    Copigneaux, Catherine
    Akerley, Wallace
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1214 - S1215
  • [36] Long-term survival of NSCLC patients with EGFR mutations treated with EGFR TKIs gefitinib or erlotinib
    Janne, R
    Sequist, L
    Lindeman, N
    Bell, D
    Huberman, M
    Meyerson, M
    Haber, D
    Lynch, T
    Johnson, B
    LUNG CANCER, 2005, 49 : S109 - S109
  • [37] Role of erlotinib in the treatment of advanced non-small-cell lung cancer patients with EGFR wild-type tumors
    Braun, Eduardo
    Bonomi, Philip
    LUNG CANCER MANAGEMENT, 2014, 3 (01) : 101 - 116
  • [38] Genetic Variations in the EGFR Gene Predicts Outcome in Advanced NSCLC Patients Treated with Erlotinib
    Larsen, Anne Winther
    Nissen, Peter H.
    Jakobsen, Kristine R.
    Demuth, Christina
    Sorensen, Boe S.
    Meldgaard, Peter
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S527 - S527
  • [39] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Kobayashi, Takashi
    Koizumi, Tomonobu
    Agatsuma, Toshihide
    Yasuo, Masanori
    Tsushima, Kenji
    Kubo, Keishi
    Eda, Seiichiro
    Kuraishi, Hiroshi
    Koyama, Shigeru
    Hachiya, Tsutomu
    Ohura, Nariaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1241 - 1246
  • [40] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Takashi Kobayashi
    Tomonobu Koizumi
    Toshihide Agatsuma
    Masanori Yasuo
    Kenji Tsushima
    Keishi Kubo
    Seiichiro Eda
    Hiroshi Kuraishi
    Shigeru Koyama
    Tsutomu Hachiya
    Nariaki Ohura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1241 - 1246
12345